Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $74.51 USD
Change Today -0.73 / -0.97%
Volume 1.2M
Q On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 4:15 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

quintiles transnational hold (Q) Snapshot

Open
$74.96
Previous Close
$75.24
Day High
$75.00
Day Low
$73.92
52 Week High
07/29/15 - $80.45
52 Week Low
10/15/14 - $51.09
Market Cap
9.1B
Average Volume 10 Days
702.4K
EPS TTM
$2.87
Shares Outstanding
122.7M
EX-Date
--
P/E TM
26.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for QUINTILES TRANSNATIONAL HOLD (Q)

quintiles transnational hold (Q) Related Businessweek News

No Related Businessweek News Found

quintiles transnational hold (Q) Details

Quintiles Transnational Holdings Inc., through its subsidiary, Quintiles Transnational Corp., provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through two segments, Product Development and Integrated Healthcare Services. The Product Development segment offers project management and clinical monitoring services, including study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, and project management for conducting various multi-site trials; and clinical trial support services comprising clinical data management, biostatistical, central laboratories, genomic laboratory, bioanalytical laboratories, cardiac safety and ECG, safety and pharmacovigilance, and phase I clinical pharmacology services. This segment also provides strategic planning and design services for biomarkers, genomics, and personalized medicine, as well as offers model-based drug development and regulatory affairs services; and consulting services, such as product development strategy, regulatory and compliance, and process and IT implementation consulting services. The Integrated Healthcare Services segment offers commercial services comprising contract sales, market entry/market exit, integrated channel management, patient engagement, and market access and commercialization consulting services; real-world late phase services, such as observational studies, comparative effectiveness studies, and product and disease registry services; and communication and health engagement services, including digital patient, and brand and scientific communications services. The company serves biopharmaceutical companies, including medical device and diagnostics companies. Quintiles Transnational Holdings Inc. was founded in 1982 and is based in Durham, North Carolina.

32,600 Employees
Last Reported Date: 03/16/15
Founded in 1982

quintiles transnational hold (Q) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.0M
Executive Chairman
Total Annual Compensation: $800.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $580.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $434.4K
Compensation as of Fiscal Year 2014.

quintiles transnational hold (Q) Key Developments

Some Major Shareholders Of Quintiles Reportedly Plan To Sell More Than $500 Million In Stock

Some major shareholders of Quintiles Transnational Holdings Inc. (NYSE:Q) reportedly plan to sell more than $500 million in stock. Sellers include investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Group plc (LSE:III) and Temasek Life Sciences Private Limited. The investors plan to unload about 7 million shares.

Quintiles Transnational Holdings Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year 2015

Quintiles Transnational Holdings Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $1,443,527,000 compared to $1,341,030,000 a year ago. Income from operations was $158,389,000 compared to $141,000,000 a year ago. Net income was $84,947,000 compared to $85,110,000 a year ago. Net income attributable to the company was $84,951,000 compared to $85,120,000 a year ago. Diluted earnings per share were $0.67 compared to $0.64 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $114,922,000 compared to $114,139,000 a year ago. Adjusted EBITDA was $189,951,000 compared to $171,793,000 a year ago. Adjusted income from operations was $164,623,000 compared to $141,948,000 a year ago. Adjusted net income was $98,706,000 compared to $85,722,000 a year ago. Diluted adjusted earnings per share were $0.78 compared to $0.65 a year ago. For the six months, the company reported total revenues of $2,791,120,000 compared to $2,648,876,000 a year ago. Income from operations was $301,606,000 compared to $282,316,000 a year ago. Net income was $171,349,000 compared to $175,324,000 a year ago. Net income attributable to the company was $171,349,000 compared to $175,303,000 a year ago. Diluted earnings per share were $1.35 compared to $1.32 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $236,530,000 compared to $236,851,000 a year ago. Net cash used in operating activities was $13,570,000 compared to net cash provided by operating activities of $38,697,000 a year ago. Acquisition of property, equipment and software was $31,924,000 compared to $35,832,000 a year ago. Adjusted EBITDA was $373,199,000 compared to $353,152,000 a year ago. Adjusted income from operations was $313,164,000 compared to $284,272,000 a year ago. Adjusted net income was $189,942,000 compared to $176,584,000 a year ago. Diluted adjusted earnings per share were $1.50 compared to $1.33 a year ago. Net debt outstanding as at June 30, 2015 was $1.69 billion. The company is increasing its full year 2015 constant currency service revenue growth guidance to a range of 8.5% to 9.5% compared to full year 2014. The company is also increasing its diluted adjusted earnings per share guidance range to $3.09 - $3.19 per share, representing growth of 14.4% to 18.1%, with diluted GAAP earnings per share between $2.84 and $2.96 per share. The annual effective income tax rate is projected to be approximately 29.5%. This financial guidance is based on the end of June foreign currency exchange rates and includes the impact of the Second Quarter Solutions transaction but does not reflect the potential impact of any future equity repurchases. Adjusted net income expected to range between $390 million and $403 million. As a result of the refinancing, the company expects net interest expense of approximately $100 million for the full year.

Quintiles and Quest Diagnostics Launch Second Quarter Solutions

Quintiles and Quest Diagnostics announced the launch of Second Quarter Solutions, their new combined clinical trials laboratory services organization. Second Quarter Solutions brings together the clinical trials laboratory operations of the two parent organizations to provide biopharmaceutical customers with the diverse capabilities and end-to-end services required in the rapidly evolving biopharmaceutical industry. The launch of Second Quarter Solutions is the result of the close of the previously announced global clinical trials laboratory services joint-venture transaction.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
Q:US $74.51 USD -0.73

Q Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $68.89 USD -1.49
ICON PLC $77.00 USD -0.99
IMS Health Holdings Inc $29.87 USD -0.34
INC Research Holdings Inc $41.01 USD -1.00
PAREXEL International Corp $65.72 USD -1.77
View Industry Companies
 

Industry Analysis

Q

Industry Average

Valuation Q Industry Range
Price/Earnings 27.4x
Price/Sales 2.2x
Price/Book NM Not Meaningful
Price/Cash Flow 26.2x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUINTILES TRANSNATIONAL HOLD, please visit www.quintiles.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.